ClinicalTrials.gg
RecruitingNCT07148739ENACTUpdated Jun 2, 2026

Ensuring Access to Optimal Therapy in CF: The ENACT Study

A Phase 4 interventional study of Elexacaftor / Ivacaftor / Tezacaftor and therapeutic drug monitoring in Cystic Fibrosis (CF), sponsored by Arkansas Children's Hospital Research Institute. Recruiting at 3 sites in United States. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Arkansas Children's Hospital Research Institute · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Planned enrollment
13th of 23
100 · median 120
Started
2025
the only one that year
Phase 4
3 of 23
2 open now
Registered
22nd of 23
by date
Lead sponsor
1 of 23
Arkansas Children's Hospital Research Institute

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 13th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 4, and was the 22nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

Read the detailed description

Understanding variation in genetic response to pharmacological treatments and personalized CFTR modulator response is crucial to the optimization of the use of these novel compounds; expansion to all patients who might benefit from them; and development of predictive biomarkers. In addition, the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them and the downstream effects is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

03

Conditions studied

  • Cystic Fibrosis (CF)

Browse trials for

Keywords

  • Cystic Fibrosis
  • CF
  • CFTR modulator
  • Pediatric CF patients
  • Elexacaftor
  • Tezacaftor
  • Ivacaftor
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype
  • age 2 years and older
  • ability to provide written and/or assent (by subject and/or legal guardian)
  • on a stable dose of triple combination CFTR modulator therapy for at least two weeks prior to Visit 1
  • clinically stable lung disease, defined as no documented acute decrease in > 10%, OR use of additional antibiotics (intravenous [IV] or oral [PO]) within 4 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • recent significant unintentional weight loss, as determined by the investigator, in the 4 weeks prior to screening
  • pregnant or breastfeeding female
  • history of alcohol or substance abuse in the 6 months prior to screening
  • participation in a study involving an intervention within 28 days (or 5 half-lives, whichever is longer) prior to screening
  • in the opinion of the Investigator, medical or psychiatric illness, or other conditions that would interfere with participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Single Arm

    Participants may be enrolled in an observational one-visit study for association of concentration with side effects. Participants may proceed to a single arm study if they have side effects to assess the feasibility of adjusting dose to maintain concentrations within an estimated effective range. Once within the range, dosing is no longer adjusted. Side effects will be evaluated as described in the protocol.

    Drug: Elexacaftor / Ivacaftor / Tezacaftor · Other: therapeutic drug monitoring

Interventions

  • DrugElexacaftor / Ivacaftor / Tezacaftor

    Drug pages: Elexacaftor · Ivacaftor · Tezacaftor

    This study will examine different dosing strategies and outcomes for triple combination CFTR modulator therapy using the drug(s) elexacaftor, tezacaftor, and/or ivacaftor in patients with cystic fibrosis.

    Also known as: Triple Combination CFTR Modulator Therapy, ETI - Elexacaftor/Tezacaftor/Ivacaftor

  • Othertherapeutic drug monitoring

    Participants who consent to the therapeutic drug monitoring study will have their dose adjusted to remain within estimated effective concentrations.

06

What researchers measure

Primary outcomes

  1. Concentration (ng/mL)

    Drug concentration of CFTR modulators

    Time frame: One time assessment for observational part of the study, up to 6 times (6 months or more) for the therapeutic drug monitoring pilot and feasibility study.

Secondary outcomes

  1. Participant Mental and Neuropsychological Health

    Participants will respond to questionnaires about anxiety, depression, suicidal ideation and other indicators of mental and neuropsychological health. Participants will complete assessments and an exam at each study visit.

    Time frame: From enrollment to the end of treatment at 6-12 months.

  2. Investigators will evaluate the feasibility of reducing dose to manage Neuropsychological Side Effects (NPSE).

    The primary goal will be to assess feasibility to monitor clinical outcomes, patient receptiveness, collection of samples, and concentration interpretation. Assessment of feasibility will include the patient acceptance of dose reduction using an acceptability questionnaire, turnaround for quantitation results by timely return of result, and clinical appropriateness for dose reduction (by monitoring clinical response).

    Time frame: From enrollment to study conclusion at 6-12 months (after all visits are completed).

  3. Response to dosing adjustments

    Outcome includes symptom assessment, spirometry, sweat chloride, weight, and TC quantitation at Visits 2-6. Investigators will monitor patients for 6 visits to assess CF and NP symptom stability under the supervision of the licensed clinical psychologist and TC concentration variability over time. At each visit investigators will re-assess dosing strategy.

    Time frame: From enrollment to study conclusion at 6-12 months, after all visits are completed.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2030, 66 months after the start.

Of 30 phase 4 interventional studies under Cystic Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's planned 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
Aug 29, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07148739
Responsible party
Jennifer Guimbellot (Principal Investigator - MD, Arkansas Children's Hospital Research Institute) — Principal investigator
First posted
Aug 29, 2025
Start date
Jun 10, 2025
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jun 2, 2026

Study contacts

Jennifer S Guimbellot, Medical Degree and License
Contact
jguimbellot@uams.edu
501-364-5365
Michelle Gillespie
Contact
GillespieM@archildrens.org
501-364-3377
Jennifer S Guimbellot, Medical Degree and License
principal investigator · Arkansas Children's Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Ivacaftor · Tezacaftor

Start the discussion